Navigation Links
ETHEX Corporation Issues Voluntary Nationwide Recall
Date:2/3/2009

Previously Issued Recall to Wholesale Level on Certain Products Expanded to Retail Level

ST. LOUIS, Feb. 3 /PRNewswire/ -- ETHEX Corporation, a subsidiary of KV Pharmaceutical Company (NYSE: KVa; KVb), is issuing a voluntary expansion to the retail level of a previously announced recall on certain products. The recall on the products listed below had previously been issued to the wholesale level, but is now being expanded to the retail level. The Company is taking this action as a precautionary measure, because the products may have been manufactured under conditions that did not sufficiently comply with current Good Manufacturing Practice (cGMP). This additional level of recall is to further remove recalled products from the marketplace.

Patients who may have these products in their possession should continue to take them in accordance with their prescriptions, as the risk of suddenly stopping needed medications may place patients at risk. Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using these products.

Expanded Recall to Retail Level Includes the Following Products:

Morphine Sulfate Extended-Release Tablets 15mg, 30mg & 60mg (All Strengths)

Morphine Sulfate Immediate-Release Tablets 15mg & 30 mg (All Strengths)

Dextroamphetamine Sulfate Tablets 5mg & 10mg (All Strengths)

Isosorbide Mononitrate Extended-Release Tablets 30mg, 60mg & 120mg (All Strengths)

Propafenone HCl Tablets 150mg, 225mg & 300 mg (All Strengths)

Any retail customer inquiries related to this action should be addressed to ETHEX Customer Service at 1-800-748-1472, faxed to ETHEX Customer Service at 314-646-3788, or e-mailed to customer-service@ethex.com. Representatives are available Monday through Friday, 8 am to 5 pm CST.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA). At this time, the Company is unable to determine when distribution of these products will resume.

Patients with questions about the recall should call the telephone number above, or contact their healthcare providers. Any adverse reactions experienced with the use of these products should also be reported to FDA's MedWatch Program by phone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, by mail at MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at www.fda.gov/medwatch

The recall announcement is posted on www.kvpharmaceutical.com.

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology distinguished products through ETHEX Corporation, a nationwide leader in generic pharmaceuticals and Ther-Rx Corporation, its branded drug subsidiary.


'/>"/>
SOURCE ETHEX Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ETHEX Corporation Voluntarily Recalls a Single Lot of Morphine Sulfate 60 mg Extended Release Tablets Due to the Potential for Oversized Tablets
2. ETHEX Corporation Voluntarily Recalls Three Lots of Dextroamphetamine Sulfate 5mg Tablets Due to the Potential for Oversized Tablets
3. ETHEX Corporation Initiated Nationwide Voluntary Recalls of Specific Lots of Five Generic Products Due to the Potential for Oversized Tablets
4. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
5. Brooke Franchise Corporation Announces Selected July Results
6. MedThink Communications Retained by NanoBio Corporation
7. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
8. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
9. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
10. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
11. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... Drs. Gregory ... hygiene symposium in Mystic, CT. Covering the process and maintenance strategies of gum ... these popular periodontal procedures. Drs. Toback and Urbanski practice as experienced periodontists ...
(Date:6/27/2017)... , ... June 27, 2017 , ... ... . Orthodontics is a dental specialty that focuses on treating alignment and occlusion ... improved aesthetics and function. , North Hollywood dentist , Dr. Garemani, ...
(Date:6/26/2017)... ... ... Center is now offering various types of dental implants to restore lost teeth. Dental implants ... such as crowns, bridges, or dentures. An implant is placed directly into the jawbone where ... tooth. , Several types of dental implants are available, including: , ...
(Date:6/26/2017)... Ruidoso, New Mexico (PRWEB) , ... June 26, ... ... sexual dysfunction, anorgasmia, and urinary leakage is revolutionizing the way women look and ... Mexico is tackling the problem of female sexual dysfunction and urinary leakage head ...
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... New patients ... from Dr. Angela Cotey, with or without a referral. Dr. Cotey is a trusted ... of this preferred tooth replacement option. , Patients with missing teeth in Fitchburg, WI, ...
Breaking Medicine News(10 mins):
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
(Date:6/8/2017)... 2017  Less than a month ago, amateur hackers ... companies, including hospital networks, in over 150 countries. ... the largest online extortion attempts ever recorded. With the ... is imperative that providers understand where the risks lie, ... — and many other very real cyber threats.  ...
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... of two Phase 2 trials of its RSV F protein ... child bearing age have been published in the journal ... have been shared in prior scientific conferences). The Company previously ... April 2014. Novavax is developing the RSV F Vaccine with ...
Breaking Medicine Technology: